World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
49220
World Ranking
4935
National Ranking
2676

Overview

Ola Landgren is affiliated with the University of Miami in the United States and has contributed extensively to research in medicine, particularly focusing on hematology and molecular biology. Their research encompasses oncology, genetics, and cancer research, with a pronounced emphasis on multiple myeloma.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields prominently featured in their work consist of:

  • Hematology
  • Molecular Biology
  • Oncology
  • Genetics
  • Cancer Research

The key research topics covered by Ola Landgren's publications are:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Cancer Genomics and Diagnostics
  • Chronic Lymphocytic Leukemia Research
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • CAR-T cell therapy research

Several recent papers authored or co-authored by Ola Landgren illustrate their scientific focus and contribution to multiple myeloma and related therapies:

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, 2020, The Lancet
  • GPRC5D-Targeted CAR T Cells for Myeloma, 2022, New England Journal of Medicine
  • Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma, 2023, Nature Medicine
  • Timing the initiation of multiple myeloma, 2020, Nature Communications
  • The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma, 2021, Nature Communications

Ola Landgren collaborates frequently with other researchers, particularly:

  • Francesco Maura
  • Malin Hultcrantz
  • Benjamin Diamond
  • Kylee Maclachlan
  • Alexander M. Lesokhin

The specialist often publishes in venues that include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood Cancer Journal
  • Blood Cancer Discovery

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study

    Ola Landgren;Robert A. Kyle;Ruth M. Pfeiffer;Jerry A. Katzmann

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

    Cecilie Blimark;Erik Holmberg;Ulf-Henrik Mellqvist;Ola Landgren

  • Solid cancers after allogeneic hematopoietic cell transplantation

    J. Douglas Rizzo;Rochelle E. Curtis;Gérard Socié;Kathleen A. Sobocinski

  • Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

    Ola Landgren;Ethel S. Gilbert;J. Douglas Rizzo;Gérard Socié

  • B-cell clones as early markers for chronic lymphocytic leukemia.

    Ola Landgren;Maher Albitar;Wanlong Ma;Fatima Abbasi

  • International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

    Antonio Palumbo;S. Vincent Rajkumar;Jesus F. San Miguel;Alessandra Larocca

  • Racial disparities in incidence and outcome in multiple myeloma: a population-based study

    Adam J. Waxman;Pamela J. Mink;Susan S. Devesa;William F. Anderson

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

    Thomas P. Giordano;Louise Henderson;Louise Henderson;Ola Landgren;Elizabeth Y. Chiao;Elizabeth Y. Chiao

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

    Meletios Dimopoulos;Hang Quach;Maria-Victoria Mateos;Ola Landgren

  • Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans

    Hashem B. El-Serag;Hashem B. El-Serag;Eric A. Engels;Ola Landgren;Elizabeth Chiao;Elizabeth Chiao

  • Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

    Ola Landgren;Gloria Gridley;Ingemar Turesson;Neil E. Caporaso

  • Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003

    Sigurdur Yngvi Kristinsson;Ola Landgren;Paul W. Dickman;Åsa Rangert Derolf

  • Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

    Sigurdur Y. Kristinsson;Gloria Gridley;Robert N Hoover;David Check

  • Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

    Neha Korde;Neha Korde;Mark Roschewski;Adriana Zingone;Mary Kwok

  • Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

    Ola Landgren;Ola Landgren;Lynn R. Goldin;Sigurdur Y. Kristinsson;Elin A. Helgadottir

Frequent Co-Authors

Magnus Björkholm
Magnus Björkholm Karolinska University Hospital
Lynn R. Goldin
Lynn R. Goldin National Institutes of Health
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
Neil E. Caporaso
Neil E. Caporaso National Institutes of Health
Ruth M. Pfeiffer
Ruth M. Pfeiffer National Institutes of Health
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Gloria Gridley
Gloria Gridley National Institutes of Health
Eric A. Engels
Eric A. Engels National Institutes of Health
Robert A. Kyle
Robert A. Kyle Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative career paths in healthcare or looking to further their education online, numerous flexible options are available. Advanced nursing programs, for example, allow medical professionals to broaden their expertise and credentials. If you're seeking the quickest way to an advanced degree, consider the shortest dnp program online to fast-track your doctorate in nursing practice.

Some students pursue accelerated formats, such as a 1 year dnp program online, balancing intensive study with work and family commitments. Those looking to start a nursing career even faster may be interested in the 6 month lpn program, which offers entry into the workforce with minimal delay.

Many specialties are also available, including mental health. Aspiring nurse practitioners can explore online pmhnp programs, preparing for advanced practice in psychiatric nursing—a growing field in the U.S. These online pathways provide flexible, reputable options for both new and experienced healthcare professionals.

Best Scientists Citing Ola Landgren

Trending Scientists

Recently Published Articles